Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of ZE74-0282 in patients with myelofibrosis and other myeloproliferative disorders

Next Previous
Trial Profile

A clinical study of ZE74-0282 in patients with myelofibrosis and other myeloproliferative disorders

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 30 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZE 74 0282 (Primary)
  • Indications Myelofibrosis; Myeloproliferative disorders
  • Focus Therapeutic Use

Most Recent Events

  • 30 Dec 2025 New trial record
  • 17 Dec 2025 According to Eilean Therapeutics media release, the company is preparing for subsequent clinical studies in patients with myelofibrosis and other myeloproliferative disorders, with the intent to transition efficiently from healthy volunteer evaluation into patient based studies focused on JAK2 V617F driven disease.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top